Oscar Health, Inc. (OSCR)
NYSE: OSCR · IEX Real-Time Price · USD
16.18
+0.17 (1.06%)
At close: Apr 22, 2024, 4:00 PM
16.27
+0.09 (0.56%)
After-hours: Apr 22, 2024, 7:27 PM EDT
Oscar Health Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Oscar Health stock have an average target of 12.82, with a low estimate of 7.50 and a high estimate of 20. The average target predicts a decrease of -20.77% from the current stock price of 16.18.
Analyst Consensus: Buy
* Price targets were last updated on Mar 22, 2024.
Analyst Ratings
The average analyst rating for Oscar Health stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 4 | 4 | 4 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $20 | Buy | Initiates | $20 | +23.61% | Mar 22, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $12 → $20 | Buy | Maintains | $12 → $20 | +23.61% | Feb 15, 2024 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $8 → $16 | Hold | Maintains | $8 → $16 | -1.11% | Feb 9, 2024 |
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $8 → $9 | Hold → Strong Buy | Upgrades | $8 → $9 | -44.38% | Nov 2, 2023 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $5 → $7.5 | Hold | Maintains | $5 → $7.5 | -53.65% | Aug 30, 2023 |
Financial Forecast
Revenue This Year
8.50B
from 5.86B
Increased by 45.00%
Revenue Next Year
9.83B
from 8.50B
Increased by 15.66%
EPS This Year
-0.16
from -1.22
EPS Next Year
0.40
from -0.16
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 8.8B | 10.6B | 12.4B |
| Avg | 8.5B | 9.8B | 11.5B |
| Low | 8.1B | 9.1B | 10.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 50.2% | 24.5% | 26.4% |
| Avg | 45.0% | 15.7% | 17.2% |
| Low | 37.9% | 6.6% | 7.3% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | -0.07 | 0.63 | 1.34 | 1.00 |
| Avg | -0.16 | 0.40 | 1.12 | 0.97 |
| Low | -0.32 | 0.24 | 0.89 | 0.93 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|
| High | - | - | 234.4% | -10.7% |
| Avg | - | - | 177.9% | -13.2% |
| Low | - | - | 121.9% | -16.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.